Treatment for dry eye
E-SWIN E-Eye is specially certified to treat MGD, allowing a unique positioning on the market. E-Eye is the global reference for IPL. Distributed over 50 countries globally, the new generation of IPL E-EYE uses ESW Vision 2nd generation patented IRPL (Intense Regulated Pulsed Light) technology. By producing perfectly calibrated and homogeneously sequenced light pulses spectrum and time period set precisely to stimulate the Meibomian Glands in order for them to return their normal function.
The working solution to treat dry eye
The results of several independent international E>Eye-studies speak for themselves…
The problem of dry eyes …
Almost one in five people know the problem: the eyes are stinging, scratchy, reddened, and feel as if filled with sand. This is also known as the dry eye syndrome. Many influences of daily (modern) life strain the eye and cause and trigger later discomfort and eye pain that may often be persistent. Redness, fatigue, blurred vision and scratchy eyes are the first signs of eye discomfort. Over the time many other symptoms and serious complications can occur, like uncomfortable changings in vision comfort and infections.
Dry eye treatment by E-Eye
It has been proven in several neurological studies that the emission on a nerve of infrared as a train of pulses leads to the creation of a micro gradient of temperature between the inner and the outer layer of the myelin sheath. This micro gradient of temperature triggers the liberation of neurotransmitters. Automatically, the parasympatic nerve is connected to the Meibomian glands by some of its branches. The neurotransmitters released will then be able to interact with the glands, stimulating the secretion and the contraction of the latter. E-Eye does not directly affect the Meibomian glands. Its action is indirect. The “flashed” areas (buborbital and zygomatic region) are the areas where the parasympathetic nerve passes.
How it works?
The dry eye treatment with E-Eye only takes a few minutes, sitting in a comfortably chair. The eyes from the patient are covered by protective eyecups. Hydrogel is applied to the lower eyelid. A series of light pulses is performed around the lower eye, gentle and non-invasive. The series is repeated in the same way for both eyes. The treatment restores the normal activity of the Meibomian gland, with very rapid improvement for the patient from the very first session. The effect of first two treatments lasts a few days up to 2 to 3 weeks. The long-lasting effect is expected for minimum 6 months up to 3 years. The E-Eye protocol comprises three to four sessions. It is recommended to repeat one application once symptoms are coming back.
As a result, the dry lipid layer receives a natural
boost of lipids, which reduces the evaporation of tear fluid and prevents the eye from drying out. In
addition, the quality of the glandular secretions is improved, and the tear film‘s lipid layer is
View IRPL clinical studies conducted with highly significant results.
The latest IRPL® technology
IE-Eye is a medical device that has been specifically designed for treating dry eye syndrome due to MGD. It generates Intense Regulated Pulsed Light by producing perfectly calibrated and homogeneously sequenced light pulses. The sculpted pulses are delivered under the shape of a train of pulses. The energy, spectrum and time period are precisely set to stimulate the Meibomian glands in order for them to return their normal function. E-Eye is the medical solution to treat and to prevent dry eyes.
Since the start of international distribution in 2016, E-Eye has set up in many countries. E-Eye is a proven solution now available in more than 50 countries around the world!
- No. 1 treatment technology for dry eye due to Meibomian Gland Dysfunction (MGD).
- In 2018, over 100.000 patients have been treated with the E-Eye!
- 90% satisfaction rate, proven efficacy on mild, medium and severe dry eye.
- Several clinical studies conducted with highly significant results.
- Up to 3 years longterm relief for your patient.
E-Eye is medical CE-marked and registered in the main global markets: CFDA (China) / TGA (Australia) / SCFDA (South Corea) / Anvisa (Brazil) / Health Canada / FDA (USA)